Interim / Quarterly Report • Oct 24, 2023
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
Company Registration Number 13139365 (England and Wales)
I am pleased to present the results for the six-month period ending 31 July 2023.
The Company's current strategic priority is to identify, evaluate and rank potential reverse takeover (RTO) targets in the energy space, utilising our strong in-house expertise. Exploration & appraisal activities have been led by Rob Jones, a former Head of Exploration at Cairn Energy, supported by Rod Murray who is an experienced oilfield operations manager.
To date, our search has focused primarily on transition energy natural gas plays, de-risked by existing discoveries and encompassing sizable upside exploration targets. Initially spreading the search through North, Central and South America, West Africa and South-East Asia the Company has compiled and high graded a number of opportunities. These are ranked and risked reflecting the best net present value (NPV) and Expected Monetary Value (EMV) value moving forward through acquisition and speculative resource addition.
Opportunities reviewed have included a West African play with 1.6 Trillion Cubic Feet (TCF) P50 prospective resource, a Gulf of Mexico 1.1TCF prospective resource and a South-East Asian 800 Billion Cubic Feet (BCF) discovery with multi TCF exploration upside potential.
The Board has been pleased with the quality of the opportunities they have had a chance to review so far and are working to compile a shortlist which they believe would be attractive to current and future shareholders. We look forward to updating the market when circumstances allow.
Moving on from the Company's £1.2m (gross) Placing and Admission to the Official List (by way of a Standard Listing) in May 2023, we have made two key appointments. Firstly, we have appointed an independent Non-Executive Chairman and secondly Allenby Capital has come on board as Financial Adviser.
The Company generated a loss of £265,777 in the six month period ended 31 July 2023 as it continued with its current strategic priority of identifying, evaluating and executing a RTO in the energy space.
Cash and cash equivalents as at 31 July 2023 were £969,924.
On admission to the London Stock Exchange on 25 May 2023, the company granted the following warrants to certain investors and Directors of the company.
| Number of Warrants | Exercise price per Ordinary Exercise Period Share |
|
|---|---|---|
| 12,000,000 1 | £ | 0.10 Two years from Admission |
| 12,000,000 1 | £ | 0.20 Two years from the completion of an Acquisition3 |
| 9,000,000 2 | £ | 0.0085 Five years from the date which the condition has been satisified4 |
| 9,000,000 2 | £ | 0.0085 Five years from the date which the condition has been satisified5 |
| 480,000 2 | £ | 0.05 Three years from Admission |
1Warrants granted to investors during the IPO Placing, pro rata to their respective investments.
2Warrants to Directors and Founder Mr Adam Dziubinski
3Warrant exercise is conditional upon, and no such Warrant may be exercised prior to, completion of an Acquisition.
4Warrant exercise is conditional upon the closing market price of the Ordinary Shares exceeding £0.10 for 20 consecutive trading days within five years of Admission. This condition has subsequently been met. The holders of these warrants are subject to lock-in agreements with the Company which would prevent the sale of these instruments and ordinary shares created therefrom. The lock-in agreements have a duration of 12 months following Admission, which took place on 25 May 2023. Subsequent to the expiry of the lockin agreements, any shares resulting from the exercise of these warrants will be subject to orderly market agreements for a further 12 months, which requires Board approval to make any sales.
5Warrant exercise is conditional upon the closing market price of the Ordinary Shares exceeding £0.20 for 20 consecutive trading days within five years of Admission.
Please refer to Note 8 for details of warrants that were granted to Directors.
I would like to take this opportunity to thank my fellow Directors, management and advisors for their continued support and hard work. I remain confident that the Company is well-placed to execute a successful RTO in the near-term.
Andy Yeo Non-executive Chairman
24 October 2023
| Notes | Six months ended 31 July 2023 (Unaudited) |
Six months ended 31 July 2022 (Unaudited) |
Year ended 31 January 2023 |
|
|---|---|---|---|---|
| £ | £ | £ | ||
| Administrative expenses | (277,680) | (135,803) | (269,049) | |
| Operating loss | (277,680) | (135,803) | (269,049) | |
| Other income | 1 | 4,425 | 8,850 | 17,700 |
| Loss before tax | (273,255) | (126,953) | (251,349) | |
| Taxation charge | 7,478 | - | - | |
| Loss for the year | (265,777) | (126,953) | (251,349) | |
| Other comprehensive income | - | - | - | |
| Total comprehensive loss for the year | (265,777) | (126,953) | (251,349) | |
| Basic and diluted loss per share (pence) | 3 | (0.96) | (0.83) | (2.72) |
| Notes | As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|---|
| £ | £ | £ | ||
| Assets | ||||
| Current assets | ||||
| Other receivables | 4 | 36,798 | 19,881 | 8,968 |
| Deferred tax asset | 9 | 29,400 | - | - |
| Cash and cash equivalents | 969,924 | 113,641 | 32,081 | |
| 1,036,122 | 133,522 | 41,049 | ||
| Total assets | 1,036,122 | 133,522 | 41,049 | |
| Liabilities | ||||
| Current liabilities | ||||
| Trade and other payables | 5 | (57,216) | (16,278) | (48,201) |
| (57,216) | (16,278) | (48,201) | ||
| Total liabilities | (57,216) | (16,278) | (48,201) | |
| Net assets/(liabilities) | 978,906 | 117,244 | (7,152) | |
| Equity | ||||
| Share capital | 6 | 378,420 | 153,000 | 153,000 |
| Share premium | 1,232,580 | 258,000 | 258,000 | |
| Share based payment reserve | 8 | 51,835 | - | - |
| Retained losses | (683,929) | (293,756) | (418,152) | |
| Total equity | 978,906 | 117,244 | (7,152) |
| Notes | Share capital |
Shares to be issued |
Share premium |
Share based payment reserve |
Retained losses |
Total equity |
|
|---|---|---|---|---|---|---|---|
| £ | £ | £ | £ | £ | £ | ||
| At 31 January 2022 | 51,000 | 360,000 | - | - (166,803) | 244,197 | ||
| Total comprehensive income Loss for the period |
- | - | - | - | (126,953) | (126,953) | |
| Transactions with owners Ordinary shares issued on incorporation |
- | - | - | - | - | - | |
| Issue of Ordinary Shares Share premium issued |
6 | 102,000 - |
(102,000) (258,000) |
- 258,000 |
- - |
- - |
- - |
| At 31 July 2022 | 153,000 | - | 258,000 | - | (293,756) | 117,244 | |
| Total comprehensive income Loss for the period |
- | - | - | - | (124,396) | (124,396) | |
| At 31 January 2023 | 153,000 | - | 258,000 | - | (418,152) | (7,152) | |
| Total comprehensive income Loss for the year |
- | - | - | - | (265,777) | (265,777) | |
| Transactions with owners Issue of Ordinary Shares |
6 | 225,420 | - | - | - | - | 225,420 |
| Share premium issued Share based payments |
8 | - - |
- - |
974,580 - |
- 51,835 |
- - |
974,580 51,835 |
| At 31 July 2023 | 378,420 | - | 1,232,580 | 51,835 | (683,929) | 978,906 |
| Notes | Six months ended 31 July 2023 (Unaudited) |
Six months ended 31 July 2022 (Unaudited) |
Year ended 31 January 2023 |
|
|---|---|---|---|---|
| £ | £ | £ | ||
| Cashflow from operating activities | ||||
| Operating loss for the year | (273,255) | (126,953) | (251,349) | |
| Adjustments for: | ||||
| Share based payments | 29,913 | - | - | |
| Movements in working capital | ||||
| (Increase)/decrease in other receivables | (27,830) | 5,870 | 16,783 | |
| Increase in trade and other payables | 9,015 | 5,119 | 37,042 | |
| Net cash used in operating activities | (262,157) | (115,964) | (197,524) | |
| Financing activities | ||||
| Proceeds from issue of share capital | 1,200,000 | - | - | |
| Net cash generated from financing activities | 1,200,000 | - | - | |
| Increase/(decrease) in cash and cash | 937,843 | (115,964) | (197,524) | |
| Cash and cash equivalents at beginning year | 32,081 | 229,605 | 229,605 | |
| Cash and cash equivalents at end of year | 969,924 | 113,641 | 32,081 |
Oneiro Energy plc (the "Company") is a company incorporated and registered in England and Wales, with a company registration number of 13139365. The address of the Company's registered office is 1st Floor, 5-6 Argyll Street, London, England, W1F 7TE.
The interim financial statements for the half-year ended 31 July 2023 are prepared in accordance with IFRS as adopted by the UK and IAS 34 'Interim Financial Reporting'. The same accounting policies are followed in this set of interim financial statements as compared with the most recent audited annual financial statements for the year ended 31 January 2023.
The financial information relating to the half-year ended 31 July 2023 is unaudited and does not constitute statutory financial statements as defined in section 434 of the Companies Act 2006. The comparative figures for the year ended 31 January 2023 have been extracted from the annual financial statements, of which the auditors gave an unqualified audit opinion. The annual financial statements for the year ended 31 January 2023 has been filed with the Registrar of Companies.
The Company's financial risk management objectives and policies are consistent with those disclosed in the year ended 31 January 2023 annual financial statements.
The half-yearly report was approved by the board of directors on 24 October 2023.
The accounting policies adopted in the preparation of the financial information for the half-year ended 31 July 2023 are consistent with those followed in the preparation of the Company's annual financial statements for the year ended 31 January 2023. An additional policy for share based payments was adopted in relation to the share warrants that were granted to Directors during the period.
The company allows for Directors to acquire shares of the company and all options and warrants are equitysettled. The fair value of options granted is recognised as an expense with a corresponding increase in equity. The fair value is measured at grant date and spread over the period during which the Directors or employees become unconditionally entitled to the options. The fair value of the options granted is measured using the Black-Scholes model, taking into account the terms and conditions upon which the options were granted. The amount recognised as an expense is adjusted to reflect the actual number of share options that vest.
At the date of authorisation of the financial statements, the following amendments to Standards and Interpretations issued by the IASB that are effective for an annual period that begins on or after 1 January 2023. These have not had any material impact on the amounts reported for the current and prior periods.
| IFRS 17 – Insurance Contracts | 1 January 2023 |
|---|---|
| IAS 8 – Definition of Accounting Estimates | 1 January 2023 |
| IAS 1 – Disclosure of Accounting Policies | 1 January 2023 |
| IAS 12 – Deferred Tax Arising from a Single Transaction | 1 January 2023 |
| Initial Application of IFRS 17 and IFRS 9 – Comparative Information | 1 January 2023 |
At the date of authorisation of these financial statements, the Company has not early adopted the following amendments to Standards and Interpretations that have been issued but are not yet effective:
| Standard or Interpretation | Effective Date |
|---|---|
| IAS 1 Classification of liabilities as current or non-current | 1 January 2024 |
| IAS 1 – Non-current liabilities with covenants | 1 January 2024 |
| IFRS 7 – Supplier finance arrangements | 1 January 2024 |
| IFRS 16 – Lease liability in a Sale and Leaseback | 1 January 2024 |
As yet, none of these have been endorsed for use in the UK and will not be adopted until such time as endorsement is confirmed. The directors do not expect any material impact as a result of adopting standards and amendments listed above in the financial year they become effective.
The preparation of financial statements in conformity with IFRS as adopted by the UK requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.
The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. The resulting accounting estimates may differ from the related actual results.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
In the process of applying the Company's accounting policies, the Directors' do not believe that they have had to make any assumptions or judgements that would have a material effect on the amounts recognised in the financial statements.
| Six months ended 31 July 2023 (Unaudited) |
Six months ended 31 July 2022 (Unaudited) |
Year ended 31 January 2023 |
|
|---|---|---|---|
| This is stated after charging/(crediting): | £ | £ | |
| Rent receivable Auditors' remuneration |
(4,425) - |
(8,850) - |
(17,700) 20,000 |
| Six months ended 31 July 2023 (Unaudited) |
Six months ended 31 July 2022 (Unaudited) |
Year ended 31 January 2023 |
|
|---|---|---|---|
| (a) Staff numbers (including directors): |
Number | Number | Number |
| Directors | 3 | 3 | 3 |
| (b) Directors' remuneration: |
£ | £ | £ |
| Remuneration for qualifying services | 12,086 | 18,173 | 33,302 |
| Total directors' costs | 12,086 | 18,173 | 33,302 |
Further details on Directors' remuneration is given in the Directors' report.
The basic and diluted earnings per share figures are set out below:
| Six months ended 31 July 2023 (Unaudited) |
Six months ended 31 July 2022 (Unaudited) |
Year ended 31 January 2023 |
|
|---|---|---|---|
| £ | £ | £ | |
| Loss attributable to shareholders | (265,777) | (126,953) | (251,349) |
| Weighted average number of shares | Number | Number | Number |
| For basic and diluted earnings per share | 27,816,796 | 12,733,333 | 9,254,795 |
| Total | 27,816,796 | 12,733,333 | 9,254,795 |
| Loss per share: | Pence per share | Pence per share | Pence per share |
| Basic and diluted (pence) | (0.96) | (0.83) | (2.72) |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| £ | £ | £ | |
| Other receivables | 33,431 | 19,881 | 7,888 |
| Prepayments | 3,367 | - | 1,080 |
| Total receivables | 36,798 | 19,881 | 8,968 |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| £ | £ | £ | |
| Trade payables | 184 | - | 184 |
| Accruals | 57,000 | - | 47,710 |
| Other taxation and social security | - | - | 74 |
| Other payables | 32 | 16,278 | 233 |
| Total trade and other payables | 57,216 | 16,278 | 48,201 |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| No. | No. | No. | |
| Brought forward | 18,000,000 | 6,000,000 | 6,000,000 |
| Issued in the year | 26,520,000 | 12,000,000 | 12,000,000 |
| At the end of the year | 44,520,000 | 18,000,000 | 18,000,000 |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| £ | £ | £ | |
| Brought forward | 153,000 | 51,000 | 51,000 |
| Issued in the year | 225,420 | 102,000 | 102,000 |
| At the end of the year | 378,420 | 153,000 | 153,000 |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| £ | £ | £ | |
| Cash and cash equivalents | 969,924 | 113,641 | 32,081 |
| Other receivables | 36,798 | 19,881 | 8,968 |
| Total financial assets | 1,006,722 | 133,522 | 41,049 |
| As at 31 July 2023 (Unaudited) |
As at 31 July 2022 (Unaudited) |
As at 31 January 2023 |
|
|---|---|---|---|
| £ | £ | ||
| Trade and other payables | 57,216 | 16,278 | 48,201 |
| Short-term financial liabilities | 57,216 | 16,278 | 48,201 |
| Total financial liabilities | 57,216 | 16,278 | 48,201 |
All financial assets and liabilities that are recognised in the financial statements are short term in nature and shown at their carrying value which is also approximate to their fair value.
On 25 May 2023, the company granted share warrants to Directors on admission to the London Stock Exchange. A summary of the warrants granted to directors is as follows:
| Warrant Holder | Number of Warrants |
Exercise price per Ordinary Share |
Exercise Period Transferrable | Exercised | ||
|---|---|---|---|---|---|---|
| Robert Francis Edwin Jones |
3,000,000 | £ | 0.0085 | 5 years from the date when the condition has been satisified1 |
No | No |
| Robert Francis Edwin Jones |
3,000,000 | £ | 0.0085 | 5 years from the date when the condition has been satisified2 |
No | No |
| Peter Roderick Gordon Murray |
3,000,000 | £ | 0.0085 | 5 years from the date when the condition has been satisified1 |
No | No |
| Peter Roderick Gordon Murray |
3,000,000 | £ | 0.0085 | 5 years from the date when the condition has been satisified2 |
No | No |
| John Michael Treacy | 480,000 | £ | 0.05 | 3 years from Admission | No | No |
1Warrant exercise is conditional upon the closing market price of the Ordinary Shares exceeding £0.10 for 20 consecutive trading days within five years of Admission.This condition has subsequently been met. The holders of these warrants are subject to lock-in agreements with the Company which would prevent the sale of these instruments and ordinary shares created therefrom. The lock-in agreements have a duration of 12 months following Admission, which took place on 25 May 2023. Subsequent to the expiry of the lockin agreements, any shares resulting from the exercise of these warrants will be subject to orderly market agreements for a further 12 months, which requires Board approval to make any sales.
2Warrant exercise is conditional upon the closing market price of the Ordinary Shares exceeding £0.20 for 20 consecutive trading days within five years of Admission.
The fair value of the share warrants at the date of grant was measure using the Black Scholes pricing model, which takes into account factors such as the option life, share price volatility and the risk free rate.
| Date of grant | Share price (£) Exercise price | (p) | Risk Free Rate | Expected term (Years) |
Expected dividend yield |
Expected volatility |
Fair value of option |
|---|---|---|---|---|---|---|---|
| 25/05/2023 | 0.06 | 0.0085 | 4.38% | 5 | 0% | 61.32% | £ 0.0241 |
| 25/05/2023 | 0.06 | 0.0085 | 4.38% | 5 | 0% | 61.32% | £ 0.0085 |
| 25/05/2023 | 0.06 | 0.05 | 4.38% | 3 | 0% | 61.32% | £ 0.0299 |
The risk-free interest rate is based on the UK 10-year Gilt yield.
The expected term represents the maximum term that the company's share options in relation to employees of the company are expected to be outstanding.
The estimated volatility is the amount by which the price is expected to fluctuate during the period. The estimated volatility for the share options was determined based on the standard deviation of share price fluctuations of the company since its listing.
The company's board of directors may from time to time declare dividends on its outstanding shares. Any determination to declare and pay dividends will be made by the board of directors and will depend upon the company's results, earnings, capital requirements, financial condition, business prospects, contractual restrictions and other factors deemed relevant by the board of directors. If a dividend is declared, there is no assurance with respect to the amount, timing or frequency of any such dividends. Based on this uncertainty and unknown frequency, no dividend rate was used in the assumptions to calculate the share based compensation expense.
| The number and weighted average exercise prices of the share warrants were as follows: | ||||||
|---|---|---|---|---|---|---|
| As at 31 July 2023 | As at 31 July 2022 | As at 31 Janaury 2023 | ||||
| No. of | Average | No. of | Average | No. of | Average | |
| shares | Exercise | shares | Exercise | shares | Exercise | |
| No. | £ | No. | £ | No. | £ | |
| Options outstanding, start of period | - | - | - | - | - | - |
| Granted | 12,480,000 | 0.0208 | - | - | - | - |
| Cancelled | - | - | - | - | - | - |
| Options outstanding, end of period | 12,480,000 | 0.0208 | - | - | - | - |
| Options exercisable, end of period | 480,000 | 0.0500 | - | - | - | - |
A share-based payment charge of £29,913 was recognised during the period in relation to the share warrants granted in the period. Additionally, a deferred tax asset amount of £21,922 was recognised directly in the share based payment reserve in respect of the estimated future tax deduction that exceeds the cumulative share based payment expense.
| Liabilities | Assets | ||||||
|---|---|---|---|---|---|---|---|
| As at 31 July As at 31 July As at 31 |
As at 31 July | As at 31 | |||||
| 2023 | 2022 | January 2023 | 2023 | 2022 | January 2023 | ||
| £ | £ | £ | £ | £ | £ | ||
| Share based payments | - | - | - | 29,400 | - | - | |
| - | - | - | 29,400 | - | - |
| Movements in the period: | 31 July 2023 | 31 July 2022 | 31 January 2023 |
|---|---|---|---|
| £ | £ | £ | |
| Net liability/(asset) at start of period | - | - | - |
| (Credit)/charge to Statement of Comprehensive Income | (7,478) | - | - |
| (Credit)/charge to Equity | (21,922) | - | - |
| Net liability/(asset) at year end | (29,400) | - | - |
The deferred tax asset set out above is related to share based payments where a tax deduction will not be received until the exercise date, which will be based on the intrinsic value of the option.
After the end of the interim period, 6,000,000 Director warrants became exercisable. The warrants are subject to lock-in agreements with the Company which would prevent the sale of these instruments and ordinary shares created therefrom. The lock-in agreements have a duration of 12 months following Admission, which took place on 25 May 2023. Subsequent to the expiry of the lock-in agreements, any shares resulting from the exercise of these warrants will be subject to orderly market agreements for a further 12 months, which requires Board approval to make any sales.
The Company has a number of shareholders and is not under the control of any one person or ultimate controlling party.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.